Please login to the form below

I have forgotten my password

Neupogen

This page shows the latest Neupogen news and features for those working in and with pharma, biotech and healthcare.

Novartis doubles down on biosimilars with Biocon alliance

Novartis doubles down on biosimilars with Biocon alliance

Previous launches have included its Glatopa version of Teva’s multiple sclerosis drug Copaxone (glatiramer acetate) and Zarxio, a variant of Amgen’s Neupogen (filgrastim).

Latest news

Novartis takes biosimilar delay complaint to Supreme Court

Novartis is appealing an earlier ruling which ordered the company to delay launch of Zarxio, its version of Amgen's white blood cell stimulator Neupogen (filgrastim) and the first biosimilar to
Novartis claims first place for its biosimilar Enbrel in US

biosimilars business after the company got a green light for its Zarxio copy of Amgen's neutropenia therapy Neupogen (filgrastim).
Novartis gets FDA panel backing for biosimilar Enbrel

The GP2015 recommendation also puts Novartis on course for a second biosimilar approval in the US after its Zarxio product, a copy of Amgen's white blood cell stimulator Neupogen (filgrastim)
Sandoz files for approval of Neulasta biosimilar in Europe

The generic drug specialist - which also sells a biosimilar version of Amgen's short-acting GCSF product Neupogen (filgrastim) - said the Neulasta filing means it is now halfway to its objective
FDA panel recommends first biosimilar antibody for approval

The drug is also only the second biosimilar to be approved in the US after Novartis/Sandoz' Zarxio (filgrastim-sndz), which is a copy of Amgen's white cell stimulator Neupogen

More from news
Approximately 8 fully matching, plus 34 partially matching documents found.

Latest Intelligence

Customer experience rules the digital age

Establishing an effective customer journey
Embracing digital disruption in pharma

LEO Innovation Lab and some of its successes to date
Biosimilars - the same, but different?

Neupogen (filgrastim).

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

AP Pharma appoints Dendreon’s Jesse Hollingsworth to lead sales

This was preceded by a period as marketing director for the oncology business unit of Amgen, where he worked on such products as Neulasta, Neupogen and Vectibix.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Senior Account Manager: Competitive salary commensurate with experience

Home based, Chief Medical Writer, Medical Communications: Excellent package

Editorial Director – Medical Education (MedComms): Neg

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Home based, Editorial Team Leader, Medical Communications: Excellent package

Client Services Director - Med Comms: Great salary and bebefits

Home based, Principal Medical Writer, Medical Communications: Excellent package

Account Manager: £40, 000 - £45, 000 benefits

Client Services Director – Healthcare Advertising - London: Neg

Strategic Planner, Healthcare Advertising: £47, 000 – £53, 000

Multi-Channel Account Managers - Road / Homebased – Full or Part...: Competitive salary

Delivery Manager/ Head of Delivery – Executive Search: Neg

Scientific Communications Director - Oncology – In House Pharma ...: Neg

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Account Director, Medical Communications: C£50 – 65, 000 benefits and bonus

Senior Medical Writer, Healthcare Advertising Agency: £45, 000 – £50, 000

Healthcare PR Director: £100, 000 – £120, 000 benefits

Senior Project Manager - Medical Writing: Great salary and bebefits

Business Unit Head, Medical Communications, London: Excellent package

Home based, Senior Medical Writer, Medical Communications: Excellent package

Account Director, Consumer Healthcare PR, Global PR agency: £50, 000 – £58, 000

Subscribe to our email news alerts

PMHub

Add my company

CMR

Specialising in medical device market research, our approach is people-centric and we thrive on making connections with clients and research...

Latest intelligence

GDPR and events. What does the pharma industry need to know?: ...
Digital trends in B2B sales - how far behind is Pharma?: The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape: Is it a solution to addressing the challenges of the value-based marketplace?...

Quick links

Infographics

Multimedia

<>